Type 1 neovascularization can be a secondary feature of central serous chorioretinopathy. In this touchOPHTHALMOLOGY interview, Dr Dinah Zur (Center for Retinal Degenerations, Ophthalmology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel) talks us through the implications of improper diagnosis of this condition for optimal management and the imaging techniques that are recommended for diagnosis.
Questions:
- What are the clinical features of type 1 neovascularization in patients who do not have age-related macular degeneration but instead have features consistent with central serous chorioretinopathy? (00:19)
- What are the implications of improper diagnosis of this condition for optimal management? (01:07)
- What imaging techniques are recommended for diagnosis? (01:51)
- What are the key take home messages of your presentation? (03:55)
The abstract ‘Type 1 neovascularisation or CSC?’ was presented at EURETINA 2022, 1–4 September 2022
Disclosure: Dinah Zur has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
